Accueil・Liste d'Actions・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Fermé

SecteurSoins de santé

9.02 2.5

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.75

Max

9.02

Chiffres clés
By Trading Economics
Revenu	-1.1B -722M
Ventes	-250M 156M
P/E Moyenne du Secteur	7.603 68.51
BPA	0.14
Marge bénéficiaire	-461.478
Employés	435
EBITDA	-966M -700M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+148.47% upside

Dividendes
By Acuity
Prochains Résultats	5 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-99M 2.2B
Ouverture précédente	6.52
Clôture précédente	9.02

BioCryst Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 août 2026, 19:36 UTC

Correlated Moves

BioCryst Pharmaceuticals Inc shares are higher today, supported by gains in the biotechnology sector. The stock remains above its earlier low despite recent trends.

3 août 2026, 19:56 UTC

BioCryst Pharmaceuticals Inc shares are lower today, continuing a downward trend since Friday. The broader market is seeing gains, contrasting with BioCryst's performance.

31 juil. 2026, 22:36 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading. No specific news was identified to explain this movement, reflecting routine performance since Friday's close.

30 juil. 2026, 20:09 UTC

BioCryst Pharmaceuticals shares are lower amid broader market volatility following mixed economic signals, including rising jobless claims and disappointing GDP growth.

29 juil. 2026, 19:35 UTC

BioCryst Pharmaceuticals Inc shares are lower amid a declining market, with no specific company news identified to explain the movement during today's session.

28 juil. 2026, 23:06 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, continuing an upward trend from Tuesday's close, despite an earlier session pullback.

27 juil. 2026, 20:01 UTC

BioCryst Pharmaceuticals Inc shares are trading higher in Monday's session, reflecting notable strength despite remaining near the lower end of their one-month trading range.

24 juil. 2026, 21:01 UTC

BioCryst Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market trends following a decline in the Nasdaq influenced by negative earnings reports.

22 juil. 2026, 21:51 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market trading, continuing a decline amid significant volatility in U.S. markets and lack of specific news.

21 juil. 2026, 17:46 UTC

BioCryst Pharmaceuticals Inc shares are higher today, continuing an upward trend since Monday. The stock remains below its 20-day moving average.

20 juil. 2026, 19:16 UTC

Correlated Moves

Shares lower amid decline in Biotechnology sub-sector and SPDR ETF.

Comparaison

Variation de prix

BioCryst Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

148.47% hausse

Prévisions sur 12 Mois

Moyen 21.89 USD 148.47%

Haut 32 USD

Bas 12 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

9 ratings

Achat

Maintien

Vente

Basé sur 9 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.